The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes

Diethelm Tschöpe1*, Markolf Hanefeld2, Juris J Meier3, Anselm K Gitt4, Martin Halle5,6, Peter Bramlage7 and Petra-Maria Schumm-Draeger8

Abstract
Metformin is, if not contraindicated and if tolerated, usually preferred over other antidiabetic drugs for the first line treatment of type-2 diabetes. The particular decision on which antidiabetic agent to use is based on variables such as efficacy, cost, potential side effects, effects on weight, comorbidities, hypoglycemia, risk, and patient preferences. However, there is no guidance how to consider these in the selection of antidiabetic drug treatment. In this work, we aimed to summarize available evidence and tried to give pragmatic treatment recommendations from a clinical practice perspective.

There are clear contraindications for some drugs in those with impaired renal and liver function and precautions in those with heart failure for the use of metformin (NYHA III-IV) and glitazones. On the other hand, GLP-1 analogs, DPP-4 inhibitors and acarbose are generally less critical and can be used in the majority of patients. We identified the following gaps with respect to the selection of antidiabetic drug treatment in patients with co-morbid disease conditions: 1) Guidelines fail to give advice on the use of specific antidiabetic drugs in patients with co-morbidity. 2) The literature is deficient in studies documenting antidiabetic drug use in patients with severely impaired renal function, diabetic retinopathy, cerebrovascular disease and systolic heart failure. 3) Further there are no specific data on patients with multiple of these co-morbid disease conditions. We postulate that differential use of antidiabetic drugs in patients with co-morbid disease constellations will help to reduce treatment related complications and might improve prognosis.

Introduction
There is appropriate guidance for the pharmacotherapy of patients with type-2 diabetes. In general metformin is, if not contraindicated and if tolerated, considered the first line antidiabetic agent [1]. If non-insulin monotherapy fails in achieving HbA1c targets over 3–6 months, a second oral agent or insulin is to be added. The particular decision on which antidiabetic agent to use is however based on variables such as efficacy, cost, potential side effects, effects on weight, comorbidities, hypoglycemia, risk, and patient preferences.

A recent position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) on a patient-centred approach in the management of patients with type-2 diabetes [2] gives an overview on how different glucose-lowering agents may impact treatment choices when co-morbid disease conditions are considered. Even at acceptable levels of glucose control, these comorbidities have a substantial impact on well-being as measured by the SF-36 and EQ-5D [3,4]. Because these considerations are important but difficult to translate into clinical practice, we aimed to summarize available evidence and tried to phrase expert opinion from a clinical practice perspective. We refrained, in general, to comment upon non-antidiabetic drugs as they are beyond the scope of the current review.

This overview was consolidated over the course of a total of two board meetings in which the authors discussed the data on antidiabetic pharmacotherapy in patients with co-morbid disease conditions. On this basis a tabular overview for pragmatic decision making from a clinical practice perspective was developed (Figure 1).
Antidiabetic therapy in obese patients

In 2010 the prevalence of obesity among adult patients with type 2 diabetes in US was 56.9%, according to the Centres for Disease Control and Prevention. This is not only important on a quantitative basis but also because obesity in patients with diabetes is associated with poor control of blood glucose, making obese patients with diabetes a high risk population for micro- and macrovascular events.

It appears that metformin is the principal choice for obese patients with type-2 diabetes because it is neutral with respect to weight. This has been shown in the United Kingdom Prospective Diabetes Study (UKPDS) in which even weight loss was observed for metformin users [5]. On the other hand, the Body Mass Index (BMI) itself appears to have no effect on the reduction of HbA1c or glycaemic control with metformin either alone or in combination with other drugs [5-9], although there are selected data to show that obese patients receiving metformin appear to have a greater chance to achieve target levels of HbA1c < 7% without additional antidiabetic drugs than patients receiving sulfonylurea (SU) or insulin [10]. Dipeptidyl peptidase-4 (DPP-4) inhibitors and bile acid sequestrants are weight-neutral [11,12]. Liraglutide and exenatide have comparable effects on weight, but liraglutide may have a greater effect than exenatide on glycemic control, when used as a second-line therapy [13]. The newer available agents, glucagon-like peptide-1 (GLP-1) agonists promote weight loss. In recent meta-analyses, GLP-1 analogs, were associated with weight loss when added to metformin [11] or to a combination therapy of metformin and SU [14].

Insulin and insulin analogues seem to induce weight gain as a recent meta-analysis showed that insulin and glitazones were associated with weight gain when added to a combination therapy of metformin and SU [14]. A 6-year follow-up of the UKPDS also showed that weight gain was more pronounced in insulin- than in SU- (and metformin-) treated patients [5]. On the other hand, glitazones, SU, and glinides are also associated to weight gain when added to metformin [11]. Despite their effect on weight gain, HbA1c reduction and glycemic control with sitagliptin, nateglinide, glyburide, SU or insulin do not seem to be affected by BMI [5-9].

Expert opinion

Metformin appears to be the primary choice for obese patients with type-2 diabetes (Figure 1). For metformin-treated

---

**Table:**

| Co-morbid disease condition | Metformin | GLP-1 analogs | DPP-4 inhibitors | Insulin | Acarbose | Glitazones | SU | Glinides | Glycaemic control |
|-----------------------------|-----------|---------------|------------------|--------|----------|------------|----|----------|------------------|
| Obesity (BMI > 30 kg/m²)    | yes       | yes           | yes              | O      | yes      | O          | O  | O        | yes              |
| Albuminuria (>20 mg/g creatinine) | O  | O            | O                | O      | O        | O          | O  | yes      | yes              |
| Impaired renal function (GFR < 60 ml/min) | no  | (O)² | (O)² | yes | (O)² | yes | (O)² | yes | yes |
| Diabetic retinopathy (Proven by fundoscopy) | O | O | O | O | O | O | O | yes |
| Cardiovascular disease (CAD, AMI, PCl, CABG) | (yes)³ | (yes)⁴ | (yes)⁴ | (yes)³ | yes | (yes)⁴ | O | O | O |
| Cerebrovascular disease (Stroke) | (yes)⁵ | (yes)⁴ | (yes)⁴ | (yes)³ | yes | (yes)⁴ | O | O | O |
| Systolic heart failure (EF <50%; NYHA ≥ II) | (yes)⁶ | (no)⁷ | (yes)⁴ | (yes)⁴ | (O)³ | yes | no | O | O | O |
| Liver dysfunction | (yes)⁸ | (no)⁹ | O | O | O | O | no | no | O |
| Severe hypoglycaemia¹ (≥ 1/yr with 3rd party assistance) | yes | (yes)⁴ | (yes)⁴ | O | yes | yes | O | O | O |
| Hospitalized patients | (O)¹⁰ | O | O | yes | O | O | O | O |
| Elderly (> 65 years) | yes | (yes)⁴ | (yes)⁴ | (yes)³ | O | O | O | O |

**Legend:**

- recommended
- neutral
- contraindicated

¹ requiring third party assistance; ² contraindicated Acarbose < 25 ml/min, DPP-4 < 50 ml/min, Exenatide < 30 ml/min, Liraglutide < 60 ml/min, SU < 30 ml/min; ³ only in those without hypoglycaemia; ⁴ no clear consensus because of a lack of data; ⁵ Metformin contraindicated within 2 weeks after stroke; ⁶ Metformin recommended in those with NYHA class I-II heart failure; ⁷ contraindicated in those with NYHA class III-IV heart failure; ⁸ Metformin recommended in hepatopathy without liver failure; ⁹ Metformin is contraindicated for patients with advanced liver failure; ¹⁰ Metformin and SU should be stopped if fasting periods or radiological contrast studies are envisioned.

**Figure 1** Co-morbidity adjusted selection of antidiabetic drugs based on expert opinion.
patients who fail to achieve targets for fasting plasma glucose of 70 to 130 mg/dl or post-prandial glucose below 180 mg/dl, second-line treatment choices in order of weight benefit would be: GLP-1 agonists, DPP-4 inhibitors, acarbose, bile acid sequestrants, and amylin analogs. If insulin treatment is indicated, a basal insulin supplementation should be considered.

**Antidiabetic therapy in patients with albuminuria**

Diabetic nephropathy is characterized by albuminuria and abnormal glomerular function and is a major cause of renal failure. The prevalence of microalbuminuria (MAU) among those with type-2 diabetes was 39% in the Developing Education on Microalbuminuria for Awareness of Renal and Cardiovascular Risk in Diabetes (DEMAND) survey [15].

In patients with MAU it has been shown that an intensified glucose lowering treatment is indicated, a basal insulin supplementation is indicated, a basal insulin supplementation would be: GLP-1 agonists, DPP-4 inhibitors, acarbose, bile acid sequestrants, and amylin analogs. If insulin treatment is indicated, a basal insulin supplementation should be considered.

**Antidiabetic therapy in patients with impaired renal function**

Diabetes is the leading cause of kidney failure, accounting for 44% of all new cases of kidney failure in 2008 in the United States [21]. The clearance of antidiabetic drugs is decreased and results in prolonged exposure to higher levels of the drug or its metabolites that may trigger adverse events. Observational data suggest that mortality risk in patients with type 2 diabetes and renal dysfunction increases with HbA1c levels < 6.5% and > 8.0%. Accordingly, HbA1c levels between 6.5% and 7.5% may be a reasonable target for these patients [22].

A number of antidiabetic drugs are contraindicated in patients when glomerular filtration rate (GFR) falls below variable thresholds, such as 25 ml/min for acarbose, 30 ml/min for exenatide and SU, 50 ml/min for DPP-4 inhibitors and 60 ml/min for metformin and liraglutide. There are scant data on the actual efficacy and safety of diabetes medications depending on patients’ renal function. Furthermore, contraindications do not necessarily match with available evidence. This is exemplified with metformin [23]: The label of metformin in the U.S. allows the prescription of metformin at or above 1.4 mg/dl serum creatinine in women and 1.5 mg/dl in men. In Germany, metformin is contraindicated in patients with a GFR < 60 ml/min. In the U.K. prescribing guidelines consider both creatinine and GFR for assessing treatment eligibility. The National Institute for Health and Clinical Excellence (NICE) recommends reviewing prescriptions when serum creatinine exceeds 1.5 mg/dl or GFR falls below 45 ml/min per 1.73 m² and to stop treatment at a serum creatinine of 1.7 mg/dl or a GFR of below 30 ml/min per 1.73 m². The uncertainty is mirrored in clinical practice when metformin is prescribed despite full knowledge of the relevant cut-offs. Nevertheless, there is no evidence from prospective comparative or observational studies that metformin confers an increased risk of lactic acidosis. This was shown in a meta-analysis from 347 comparative trials and cohort studies [24].

Insulin is generally considered to be safe in patients with a reduced kidney function. When there is a reduction of renal function, its half-life is prolonged because of lower levels of degradation [25]. This has been shown to increase the frequency of hypoglycaemic events which may be five times as frequent as in patients without kidney disease [26].

Available pharmacokinetic and clinical studies suggest that DPP-4 inhibitors may be safe in patients with renal impairment. Because of their variable degree of renal clearance (except for linagliptin), they may however need dose adjustment. Additionally, DPP-4 inhibitors have a decreased risk of hypoglycemia [27].

As outlined above, glitazones may have a protective effect to either prevent or slow the progression of diabetic nephropathy.
kidney disease. This drug class may therefore be preferred over other drugs for the treatment of patients with diabetes. It further undergoes hepatic metabolism and has been demonstrated to be effective without an increased risk of hypoglycemia in patients with chronic kidney disease [28]. However, fluid retention may be accentuated and appropriate measures should be taken.

Expert opinion
Impairment of renal function is an important comorbidity to be considered when selecting antidiabetic drugs (Figure 1). When taking a GFR < 60 ml/min metformin is contraindicated as is liraglutide. Other thresholds apply to DPP-4 inhibitors (<50), exenatide and SU (<30) and acarbose (<25 ml/min). Generally recommended are glitazones, glinides, insulin, and more recently DPP-4 inhibitors, although the dose may have to be adjusted.

Antidiabetic therapy in patients with diabetic retinopathy
Diabetic retinopathy is the most frequent vascular complication and the most feared by patients. The prevalence ranges in newly diagnosed patients ranges from 0 to 30% [29]. Diabetic macular edema (DME) was present in 4.1% of type-2 diabetic patients not requiring insulin and 9.1% in those with insulin in the longitudinal Exeter Diabetic Retinopathy Screening Program in the UK [30,31].

Optimal glycaemic control is crucial for preventing the progression of retinopathy. Furthermore, an early achievement of good glycaemic control in the course of diabetes has been shown to delay progression of diabetic retinopathy independent of glucose control [32]. The use of retinal laser photocoagulation together with intravitreal therapy with steroids, and more recently, with biologicals has enabled a second line therapy for DME [33].

Among the antidiabetic drugs insulin has been shown to directly influence retinal blood flow, vascular tone and angiogenesis [34]. For glitazones, the UKPDS demonstrated for each 1% reduction in HbA1c level a corresponding 31% reduced risk of onset or progression of diabetic retinopathy over 9 years of follow-up [32]. Nevertheless, TZDs have been reported to increase the risk of DME in a prospective cohort study [35], but data from a subgroup of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) eye substudy did not demonstrate a conclusive link between TZD use and DME [36].

Expert opinion
No conclusive recommendations can be derived based on the available literature (Figure 1). All agents are about as good for patients with diabetic retinopathy. Since the Steno-2 study showed that intensive therapy significantly reduced the risk of retinopathy by about 60% in type-2 diabetes patients with MAU [20], it seems justified an intensive therapy to control glucose more tight than in those without retinopathy.

Antidiabetic therapy in patients with cardiovascular disease
Coronary artery disease (CAD) is the most common cause of morbidity and mortality in patients with type-2 diabetes. In 2004, heart disease was noted on 68% of diabetes-related death certificates among people aged 65 years or older in the United States [21]. It has been postulated that metformin might promote CAD [37] and is known to bear the additional risk of lactic acidosis, especially in patients with recent myocardial infarction [38]. Fisman et al. even found an increase of mortality in CAD patients receiving metformin after a 5-year follow-up [39]. These findings should, however, be considered with caution, since the study was nonrandomized. A direct comparison of metformin with other antidiabetic drugs is only available from two retrospective cohort studies. The first included 8,494 patients after myocardial infarction in Denmark and found lower mortality rates for metformin than for SU users [40]. The second included patients with a prior diagnosis of ischemic heart disease treated with metformin and documented a lower all-cause mortality for metformin than for either SU or repaglinide [41]. Nevertheless, a recently published meta-analysis could not demonstrate the benefit/risk ratio of metformin [42]. Therefore, further studies are warranted to clarify the effects of metformin on cardiovascular mortality and morbidity among patients with type 2 diabetes.

A meta-analysis of 35 trials including 8,478 patients examined the effect of insulin on mortality in the hyperglycemic critically ill patient, mostly after myocardial infarction [43]. It demonstrated that insulin decreased short-term mortality by 15%. A considerable benefit was noted in patients with type-2 diabetes mellitus (RR 0.73; 95%CI 0.58-0.90) [44]. In the Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction 2 (DIGAMI 2) trial glucose-insulin infusion failed to result in a survival benefit however [45].

Acarbose is the most extensively studied alpha-glucosidase inhibitor. In STOP-NIDDM subjects with prediabetes and early diabetes were included and suggested that acarbose was associated with a 49% risk reduction in cardiovascular events [46].

SU, on the other hand, have been reported to reduce myocardial blood flow, increase infarct size, and to increase early mortality after direct angioplasty for acute myocardial infarction. These untoward effects have been reported more so for the first-generation SU such as tolbutamide [47] than for second-generation compounds. However, the aforementioned Danish registry found no difference with respect to the type of SU as to 30-day
Antidiabetic therapy in patients with cerebrovascular disease

In 2004, stroke was noted on 16% of diabetes-related death certificates among people aged 65 years or older in the United States and the risk for stroke is 2 to 4 times higher among people with diabetes [21]. When considering antidiabetic treatment in stroke patients three different situations have to be considered. 1) Preadmission use of antidiabetic drugs; 2) antidiabetic drug use after acute stroke and 3) antidiabetic drug use in patients with anamnestic stroke.

1) In a Danish follow-up study of 4,817 patients hospitalized with ischemic stroke between 2003 and 2006 [50] the preadmission use of metformin, insulin, and patients without antidiabetic pharmacotherapy had a lower 30-day mortality compared with users of SU. However, no significant differences were observed in 1-year mortality rates. TZDs were shown to reduce infarct volume and improve neurologic function following transient middle cerebral artery occlusion in rats [51].

2) Antidiabetic drugs during acute stroke are based on the association of hyperglycemia with poor outcome after acute ischemic stroke. The 2007 American Heart / American Stroke Association guidelines suggest treating at lower glucose levels based on expert opinion [52]. One of the few studies investigating pharmacotherapy in this situation was the Glycemia in Acute Stroke study (GLIAS), a multicenter, prospective, and observational cohort study of 476 acute ischemic stroke patients [53]. Capillary blood glucose ≥155 mg/dl was associated with a 4-fold increase in the odds of poor outcome at 3 months after adjustment for age, gender, hypertension, diabetes, stroke severity, admission glycemia, and infarct volume. The UK Glucose Insulin Stroke Trial (GIST-UK) suggests that most acute stroke patients will only have mild to moderate increases in plasma glucose at presentation (median 7.6 mmol/l) with minimal insulin requirement as a consequence [54]. Metformin is contraindicated in patients within 2 weeks after stroke.

3) We found no data to prefer any antidiabetic drug over another in patients with anamnestic stroke.

Expert opinion
In patients with cardiovascular disease, SU or glinides should rather be avoided and other treatment options preferred instead (Figure 1). Because of the risk of hypoglycemia blood glucose targets to be met are suggested to be less tight compared to patients without cardiovascular disease.

Antidiabetic therapy in patients with (systolic) heart failure

Patients with type-2 diabetes are at high risk for developing systolic heart failure. In a population based cohort (Saskatchewan Health database, Canada) of patients with recent-onset type-2 diabetes the incidence was 6% over 5.2 years [55]. Pharmacotherapy is particularly difficult in this patient group as anti-diabetic medication may impair myocardial energy metabolism, thus influencing symptoms and clinical outcome. Although metformin is contraindicated in these patients in some countries, a recent systematic review by Eurich revealed that treatment with metformin may be associated with lower mortality rates, lower rates of all cause hospital admission, and less adverse events [56]. Data from the UKPDS showed that the risk for heart failure was not significantly different between the groups treated with metformin and its controls [57]. Furthermore, a study conducted in Denmark prospectively followed 10,920 patients hospitalized for the first time for heart failure in 1997–2006 and who were receiving metformin, SU and/or insulin. The study showed that treatment with metformin was associated with a low risk of mortality in diabetic patients with heart failure compared with treatment with SU or insulin [58].

Data available for acarbose in patients with heart failure are limited. In a meta-analysis of seven randomized, controlled studies with a minimum treatment duration of 52 weeks in type-2 diabetic patients and no heart failure at baseline incident heart failure was rare (about1%) and there was a trend towards a reduced incidence of heart failure with acarbose (HR 0.55 (95%CI 0.21-1.45) [59]. Insulin has been found to have positive inotropic effects on myocardial tissue and improved hemodynamics in patients with systolic heart failure. A retrospective cohort
study in 16,417 patients with diabetes and a primary diagnosis of heart failure found no association between the use of insulin and mortality in comparison to other antidiabetic drugs [60].

Expert opinion
It appears that glitazones and, in NYHA III-IV heart failure, metformin should not be used in patients with heart failure (Figure 1). Other drugs such as insulin, SU and glinides are less likely to produce untoward effects. Generally preferred are drugs such as metformin (NYHA I-II), acarbose and GLP-1 analogs / DPP-4 inhibitors although the evidence base for the recommendation of the latter is weak.

Antidiabetic therapy in patients with liver dysfunction
Liver dysfunction, particularly non-alcoholic fatty liver disease (NAFLD), and type 2 diabetes frequently coexist. Indeed, 49–62% of type 2 diabetes patients have NAFLD [61]. NAFLD may be a marker of cardiovascular risk and mortality in type 2 diabetes patients.

Treatment of type 2 diabetes in patients with liver dysfunction is complex as many OADs may be contraindicated due to the risk of hypoglycemia which may be magnified, and therefore doses may also need to be adjusted. There are only a few reported cases of hepatotoxic side effects for metformin [62], but there may be an increased risk of developing lactic acidosis in the setting of impaired liver function. Therefore, metformin is contraindicated for patients with advanced liver disease. Nevertheless, the risk of lactic acidosis associated with metformin seems to accentuate in patients with multiple comorbidities, particularly when there is an acute deterioration [63]. If a patient has stable liver dysfunction and few comorbidities, metformin is likely to be reasonably safe, but the dose should be reduced to 1500 mg daily maximum and it should be discontinued if renal or liver function worsens [64-66].

Insulin therapy is probably the safest and most effective therapy in patients with liver dysfunction, with the limitation that increased risk of hypoglycemia in such patients requires extra care with insulin dosage. Regarding SU and glinides, the existence of increased risk of hypoglycemia due to reduced hepatic gluconeogenesis should also be considered. Indeed, glinides are contraindicated in the setting of liver dysfunction because they are mostly cleared through the liver, and SU are contraindicated in advanced liver failure.

Data regarding the use of DPP-4 inhibitors in patients with liver disease are currently lacking.

Patients with moderate liver dysfunction can take sitagliptin or exenatide [67,68]. Vildagliptin is contraindicated in patients with liver dysfunction as clinical studies showed that high doses of this drug increased hepatic transaminases in some patients [69].

Expert opinion
Type 2 diabetes patients with liver dysfunction are at increased risk of cirrhosis, liver failure and hepatocellular carcinoma. Identification and tight control of metabolic risk factors remains the mainstay of treatment. Although based on the available literature no conclusive recommendations can be derived, given that OADs are contraindicated in patients with advanced liver disease, insulin treatment remains the available option for glycemic control.

Antidiabetic therapy in patients with episodes of severe hypoglycaemia
Hypoglycemia is the principal reason that blood glucose targets are not achieved in many patients and has been reported to occur at 10 to 70 per 100 patient years [70]. This is associated with an increased rate of cardiovascular and total mortality [71]. While acarbose, metformin, pioglitazone, and incretine-based therapies are not associated with hypoglycemia, a mono- or combination therapy with insulinotropic OADs such as SU or glinides and insulin have been associated with an increased risk. In the UKPDS 16% of SU and 36% of insulin treated patients experienced hypoglycemia [57]. A later study reported substantially higher rates for glibenclamide (38%) [72] which would alleviate the difference between SU and insulin [70]. Furthermore, the risk of hypoglycemia is strongly dependent on the choice of insulin. Long-acting (analog) insulins have a lower propensity to induce severe hypoglycemia compared to neutral protamine Hagedorn (NPH) insulin. Regarding short acting insulins, a meta-analysis was conducted to assess its effects compared to regular human insulin [73]. Their results suggested only a minor benefit of short acting insulin analogues in terms of incidence of hypoglycemic events.

Expert opinion
In patients with a history of (severe) hypoglycemia drugs such as SU, glinides and insulin should be avoided and less stringent blood glucose targets pursued (Figure 1). On the other hand, metformin, GLP-1 analogs / DPP-4 inhibitors, acarbose and glitazones appear to confer a low risk and should be preferred.

Antidiabetic therapy in hospitalized patients
Diabetes is associated with increased hospital admission and length of hospital stay [74] and there is much evidence that type 2 diabetes increases inpatient morbidity and mortality [75,76]. Given the particular conditions of in-hospital patients, their treatment requires more flexible strategies to treat hyperglycemia [69].
Current guidelines for inpatient patients with diabetes recommend that the glucose concentration target value should be maintained in the 140 to 180 mg/dL range as long as these values can be achieved safely [77]. Lower targets can also be considered but it is of utmost importance to avoid hypoglycemic events. However, one should bear in mind that the effect of hyperglycemia and mortality rate among patients with diabetes in surgical, medical and cardiac intensive care units depends on the admission diagnosis, as shown in a study by Falciglia et al. [78].

Insulin is considered the standard of inpatient glucose management [77]. Nevertheless, if the hospital stay is expected to be short and metabolic derangements are unlikely to occur, patients may continue their home regimens. After fasting periods, OADs should be only continued after the first normal meal. Indeed, there are special recommendations for SU and metformin. Temporarily discontinuing treatment with SU is recommended if fasting periods are expected due to increased risk of hypoglycemia [79]. Metformin should be discontinued 48 hours before the intended procedure and not resumed until the patient tolerates oral food intake and there are no other contraindications. Insulin can be administered when OADs are temporarily discontinued. Metformin is also contraindicated in contrast studies as iodinated radiological contrast media may lower the glomerular filtration rate with the risk of causing renal failure. Therefore, metformin should be discontinued at least 24 hours before the contrast study and restarted 48 hours afterward if normal renal function is confirmed. Similarly, SU should be also temporarily stopped before radiological tests, as they are mainly cleared through the kidneys. On the other hand, it should be also considered that high-dose glucocorticoid treatment increments the insulin requirement. Specifically, insulin dose should be adjusted postprandially and 8 to 12 hours after glucocorticoid administration [79].

Expert opinion
In view of the many restrictions on the use of oral antidiabetic drugs, temporary insulin treatment remains the most practical means of glycermic control for many hospitalized patients with type 2 diabetes. Glucose-lowering strategies must be chosen individually for each patient, with consideration of the relevant comorbidities and special conditions.

Antidiabetic therapy in elderly
The majority of patients have to be considered “elderly” when an age above 65 years is used as a threshold. “The elderly” however is a heterogeneous group with varying physiologic profiles, functional capabilities, and life expectancy. While some are actually “young”, many suffer from multiple co-morbidities for which specific considerations have been summarized above [80].

The risk of hypoglycemia is increased in elderly patients due to impaired renal and hepatic function, drug interaction and malnutrition [81] and a loss of sensitivity towards hypoglycemia has been reported [82]. Thus, HbA1c targets can, correspondingly, be less stringent [83]. Furthermore, a proper balance of lowering blood glucose and not getting too low is difficult to accomplish in the elderly. This is particularly true for SU in which the risk of hypoglycemia is increased by 36% in the elderly compared with younger adults.

Substantial gastrointestinal side effects may limit the use of alpha-glucosidase inhibitors particularly in older patients. There is limited information on the use of DPP-4 inhibitors in the elderly. DPP-4 inhibitors may, however need their dose adjusted (see section on nephropathy). There are not sufficient data on exenatide use in the elderly. It may be beneficial in elderly patients with reduced mobility who could benefit from weight loss, whereas it is less optimal for frail, normal weight adults. However, trials in the elderly have not been performed in larger cohorts.

A recent study investigated the efficacy and safety of adding once-daily insulin glargine to patients’ current OAD treatment and compared this to a strategy of increasing OAD doses in the elderly with poor glycemic control [84]. During the observation, HbA1c was reduced by 1.5% in insulin treated vs. 0.6% in OAD treated patients. Mean fasting blood glucose decreased by 29 and 15% and insulin treated patients had fewer hypoglycemic events. The results suggest that the addition of insulin glargine to oral antidiabetic drugs is safer with respect to hypoglycemia but as effective in elderly patients.

Expert opinion
Age is not a co-morbid disease condition per se but usually a constellation that increases the likelihood of co-morbid diseases such as those outlined above. Therefore most of the treatment recommendations for the elderly have to rely on other co-morbidities (Figure 1). Preferred drugs in the older patients should, ideally, not be cleared by the kidney and have a low risk of adverse cardiovascular effects or hypoglycaemia. Generally metformin, GLP-1 analogs / DPP-4 inhibitors and long-acting insulin should be preferred over other treatment options (SU, glinides and glitazones).

Perspectives
Randomized, controlled trials often employ narrow inclusion criteria, enrolling patients at a low risk for complications, a low degree of co-morbidity and to avoid the enrollment of patients with adverse effects or poor
adherence. We identified the following gaps with respect to the selection of antidiabetic drug treatment in patients with co-morbid disease conditions: 1) Guidelines fail to advice on the use of specific antidiabetic drugs in patients with co-morbidity. 2) The literature is deficient in studies documenting antidiabetic drug use in patients with severely impaired renal function, diabetic retinopathy, cerebrovascular disease and systolic heart failure. 3) Further there are no specific data on patients with multiple of these co-morbid disease conditions.

Competing interests
Basis for the preparation of this article were two Advisory Board Meetings. For the participation at these board meetings members received financial compensation by Sanofi Aventis Deutschland GmbH. The authors were free in the selection of content and the decision to publish the results. They take full responsibility for the content of this article. Diethelm Tschöpe and Peter Bramlage serve as guarantors. DT, MH, JIM, AKG, MH, PB and PMSD received consultancy fees, attended advisory boards and have held lectures for a number of pharmaceutical companies producing antidiabetic drugs including sanofi-aventis.

Authors' contributions
The present manuscript has been developed over the course of a total of two board meetings in which all authors gathered and discussed the data on antidiabetic pharmacotherapy in patients with co-morbid disease conditions. PB assembled the manuscript and screened the literature for important intellectual content. All authors read and approved the final manuscript.

Author details
1Herz- und Diabetestzentrum Nordrhein-Westfalen in Bad Oeynhausen, Universitätsklinik der Ruhr Universität, Bochum, Germany. 2Centre for Clinical Studies Professor Hanefeld, Dresden, Germany. 3Department of Medicine I, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany. 4Institut für Herzinfarktforschung Ludwigshafen, Ludwigshafen, Germany. 5Zentrum für Prävention und Sportmedizin an der TU München, München, Germany. 6German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany. 7Institut für Pharmakologie und präventive Medizin, Mahlow, Germany. 8Med. Klinik 3, Endokrinologie, Diabetologie und Angiologie, Klinikum München-Bogenhausen, München, Germany.

Received: 25 March 2013 Accepted: 27 March 2013 Published: 10 April 2013

References
1. American Diabetes Association: Standards of medical care in diabetes–2013. Diabetes Care 2013, 36(Suppl 1):S11–S66.
2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Trasaris A, Wender R, Matthews DR: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55(8):1577–1596.
3. Wemmelhøj PR, Gorter KJ, van Stel HF, Rutten GE: Both cardiovascular and non-cardiovascular comorbidity are related to health status in well-controlled type 2 diabetes patients: a cross-sectional analysis. Cardiovasc Diabetol 2012, 11:121.
4. Waser J, Bramlage P, Gitt AK, Binz C, Krekler M, Deeg E, Tschöpe D: Co-morbidity but not dysglycaemia reduces quality of life in patients with type-2 diabetes treated with oral mono- or dual combination therapy – an analysis of the DiAbRegis registry. Cardiovase Diabetol 2013, 12:51.
5. United Kingdom Prospective Diabetes Study Group: United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann intern Med 1998, 128(3):165–175.
6. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007, 30(8):1979–1987.
7. Aschner P, Kottelft HL, Guo H, Sunga S, Williams-Herma, D, Kaufman KD, Goldstein G: Efficacy and safety of monotherapy with sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12(9):565–567.
8. Scott R, Loes S, Davies MJ, Engel GG: Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008, 10(1):959–969.
9. Gerich J, Raskin P, Jean-Louis L, Purnakayastha D, Baron MA: PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 2005, 28(8):2093–2099.
10. Turner RC, Cull CA, Figh G, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49), UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281(12):2005–2012.
11. Prungl OJ, Scholle JM, Talwar M, Coleman CI: Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and glycoprotein A in type 2 diabetes. JAMA 2010, 303(14):1410–1418.
12. Meneghini LF, Orozco-Beltran D, Khunti K, Caputo S, Damil T, Liebl A, Ross SA: Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab 2011, 96(11):3337–3353.
13. Fakhrouy WK, Lereun C, Wright D: A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010, 86(4):44–57.
14. Gross JL, Kramer CK, Leitao CB, Hawkins N, Schan A, Pinto LC, Rodrigues TC, Azevedo MJ: Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 2011, 154(10):672–679.
15. Parving HH, Lewis JB, Ravd M, Remuzzi G, Hunsicker LG: Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2009, 66(1):257–263.
16. Bousageon R, Bejan-Angoulvant T, Saadatian-Ehah M, Lafont S, Bergeonneau C, Cassai B, Erdpedinger S, Wright JM, Guefetyer F, Cornu C: Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011, 343:d169.
17. Haffner S, Raskin J, Wilmore JH, Kuller LH, Xiang B, Zhang YL, Xie X, She L, Roddick JC, Vupputuri S, Lachin JM, Fox CS: Two-year efficacy and safety of initial combination therapy with nateglinide and metformin in patients with type 2 diabetes. Diabetes Care 2007, 30(10):2443–2447.
18. Lachin JM, Viberti G, Weston WM, Heise M, Porter LE, Freed MI: Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003, 17(1):7–12.
19. Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358(6):580–591.
20. Centers for Disease Control and Prevention: 2011 National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States. http://www.cdc.gov/diabetes/pubs/factsheet11.htm.
21. Shurawal S, Hermelgamin B, Lin M, Majumdar SR, Klarenbach S, Manns B, Bello A, James M, Turin TC, Tonelli M: Association between glycosylated hemoglobin and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 2011, 171(21):1920–1927.
22. Lipska CJ, Bailey CJ, Inzucchi SE: Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011, 34(6):1431–1437.
23. Salzgeber F, Geyrer E, Pasternak GA, Salzgeber EE: Risk of fatal and non-fatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010, 4:CD002967.
24. Rabin R, Ryan NP, Duckworth WC: The renal metabolism of insulin. Diabetes Care 1984, 7(2):351–357.
25. Muhlhauser I, Toth G, Sawicki PT, Berger M: Severe hypoglycemia in type I diabetic patients with impaired kidney function. Diabetes Care 1991, 14(4):344–346.
26. Golightly LK, Drayna CC, McDermott MT: Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet 2012, 51(8):501–514.
28. Chapelsky MC, Thompson-Cullin K, Miller AK, Sack M, Blum R, Freed MI: Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol 2003, 43(3):252–259.

29. Williams R, Ainey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A: Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye (Lond) 2004, 18(6):853–893.

30. Ling R, Ramsowk V, Taylor D, Jacob J: Longitudinal study of a cohort of people with diabetes screened by the Exeter Diabetic Retinopathy Screening Programme. Eye (Lond) 2002, 16(2):140–145.

31. Chen E, Looman M, Laouri M, Gallagher M, Van Nuys K, Lakdawalla D, Fortuny J: Burden of illness of diabetic macular edema: literature review. Can Med Res Opin 2010, 26(7):1587–1597.

32. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359(15):1577–1589.

33. Romero-Aroca P: Managing diabetic macular edema: The leading cause of diabetes blindness. World J Diabetes 2011, 26(9):98–104.

34. Anfossi G, Russo I, Dorojono Z, Trovati M: Antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabetol 2009, 8:38.

35. Michelin R, Le Chappeau R, Ory D, Petrucci-Mandara P: Increased metformin-associated mortality over a 5-year follow-up. Diabetes Metab Res Rev 2010, 26(4):265–266.

36. Fineman EZ, Tenenbaum A: A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabetol 2009, 8:38.

37. Monnier M, Marchioni N, Mascetti G, Mannucci E: Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease. Int J Cardiol 2006, 122(2):247–251.

38. Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucheron M, Bosquet JP, Kasai B, Mosau A, Gatefier F, Cornu C: Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 2012, 9(4):e1001204.

39. Pittas AG, Siegel RD, Lau J: Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials. Arch Intern Med 2004, 164(18):2005–2011.

40. Malmberg K, Ryden L, Elinsson S, Herlitz J, Nicoli P, Waldenstrom A, Wedel H, Selin L: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995, 26(1):57–65.

41. Malmberg K, Ryden L, Wedel H, Birkeland K, Bootrana A, Didotek K, Elinsson S, Fisher M, Harnsten A, Herlitz J, Hildrethrand F, MacLeod K, Laosko M, Tor-Pedersen C, Waldenstrom A: Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2) effects on mortality and morbidity. Eur Heart J 2006, 27(15):650–661.

42. Chaissin JL, Josse RG, Gomis M, Ranefeld M, Kasakia L, Laasko M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359(9323):2072–2077.

43. Meinert CL, Knatterud GL, Prout TE, Kintz CR: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970, 19(Suppl):780–830.

44. Horsdal HT, Johnsen SP, Sonderegger F, Runberg J: Sulfonylurea and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study. Diabetes Metab Res Rev 2009, 25(6):515–522.

45. Schramm TK, Gidason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbol EL, Kober L, Norgaard ML, Madsen M, Hansen PR, Torp-Pedersen C: Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011, 32(35):1900–1908.

46. Horsdal HT, Meinert F, Runberg J, Johnsen SP: Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study. J Stroke Cerebrovasc Dis 2012, 21(8):717–725.

47. Blankenship D, Niemi J, Hillew E, Karl M, Sundararaman S: Oral pioglitazone reduces infarction volume and improves neurologic function following MCAO in rats. Adv Exp Med Biol 2011, 701:157–162.

48. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Ghashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF: Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007, 38(5):1655–1711.

49. Fuentes B, Cottoca-Cansubaco MA, Sanjose B, Castillo J, Leira R, Serena J, Vivancos J, Davaio A, Gil-Nunez A, Egido J, Deza-Tedor J: Persistent hyperglycemia >155 mg/dl in acute ischemic stroke patients: how well are we correcting i2: implications for outcome. Stroke 2010, 41(10):2362–2365.

50. Gray CS, Hildreth AJ, Sanderson PC, O’Connell JE, Johnston DE, Cartledge NE, Bamford JM, James OF, Alberti KG: Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 2007, 6(5):397–406.

51. Leung AA, Eurch DT, Lamb DA, Majumdar SR, Johnson JA, Blackburn DF, McIntosh FA: Risk of heart failure in patients with recent-onset type 2 diabetes: population-based cohort study. J Card Fail 2009, 15(2):152–157.

52. Eurch DT, McIntlarre FA, Blackburn DF, Majumdar SR, Tsusuki TR, Varney J, Johnson JA: Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007, 335(7618):497.

53. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131):837–853.

54. Anderson C, Olesen JB, Hansen PR, Weeke P, Norgaard MR, Jorgensen CH, Lange T, Abildstrom SZ, Schramm TK, Vaag A, Kober L, Torp-Pedersen C, Gislason GH: Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia 2010, 53(12):2546–2553.

55. Hanefeld M, Capayat M, Petrovitsch T, Neuser D, Petzina D, Rupp M: Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004, 25(10):10–16.

56. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM, Thaizolindinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005, 111(3):583–590.

57. Gupte P, Amarapurkar D, Agal S, Bahjil R, Kulshehra P, Pramanik S, Patel N, Madan A, Amarapurkar A, Haefezunissa: Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004, 19(8):854–858.

58. Kotoh E: Possible metformin-induced hepatotoxicity. Am J Geriatr Pharmacother 2005, 3(4):270–273.

59. Khan R, Foster GR, Chowdhry TA: Managing diabetes in patients with chronic liver disease. Postgrad Med 2012, 124(1):130–137.

60. Ahmed MH, Byrne CD: Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2009, 11(3):188–195.

61. Garnis GA, Fruci B, Maza A, De Siena M, Abanovela S, Gulletta E, Ventura V, Greco M, Abenavola L, Belfore A: Metformin versus dietary treatment in nonalcoholic hepatic steatoasis: a randomized study. Int J Obes (Lond) 2010, 34(12):1255–1264.

62. Marcheini G, Brol M, Bianchi G, Tomassetti S, Zoli M, Melchionda N: Metformin in non-alcoholic steatohepatitis. Lancet 2001, 358(9285):893–894.

63. Migoya EM, Stevens CH, Bergman AJ, Luo WL, Laster N, Christensen SC, Davies MJ, Wagner JA, Herman GA: Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009, 16(1):e165–e170.
68. Nielsen LL, Okerson T, Holcombe J, Hoogwerf B: Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. J Diabetes Sci Technol 2008, 2(2):255–260.

69. Breuer TG, Meier JJ: Inpatient treatment of type 2 diabetes. Dtsch Arztebl 2013, 109(28):466–474.

70. UK Hypoglycaemia Study Group: Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007, 50(6):1140–1147.

71. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neil B, MacMahon S, Grobbbee DE, Kengne AP, Marmo M, Heller S: Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010, 363(13):1410–1418.

72. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz KB, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32(11):193–203.

73. Bremer JP, Jauch-Chara K, Hallschmid M, Schmidt S, Schultes B: Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 2009, 32(8):1513–1517.

74. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009, 53(3):298–304.

75. Papa G, Fedele V, Chiavetta A, Lorenti I, Leotta C, Luca S, Rabuazzo AM, Piro S, Alagona C, Spadaro L, Purrello F, Pezzino V: Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Acta Diabetol 2008, 45(1):53–59.